Chinese Cancer Drugs Take Center Stage at ASCO 2026, Winning Direct Showdowns with Global Leaders
The 2024 ASCO meeting marked a turning point for China’s home‑grown oncology medicines. After years of single‑arm, mechanism‑focused studies, Chinese firms are now pitting their drugs head‑to‑head against the world’s standard treatments.
One highlight was Zejin Pharma’s PD‑1/TIGIT bispecific antibody ZG005 combined with bevacizumab, presented in a Phase II trial of 95 liver‑cancer patients. Although promising, the data still need validation in larger Phase III studies that require at least 300 participants per arm.
More striking were the results from the OptiTROP‑Lung05 trial, where a Chinese TROP2‑ADC (sac‑TMT) was paired with Keytruda. The combination halted disease progression in more than half the patients (median PFS not reached) and cut the risk of progression or death by 65% (HR 0.35). At 12 months, 62% remained progression‑free versus 29% on Keytruda alone, and the objective response rate jumped to 70% from 42%. This is the first Phase III proof that an ADC plus immunotherapy can beat Keytruda monotherapy.
Tongyuankang’s third‑generation EGFR‑TKI (TY‑9591) also earned a “superiority” label by beating osimertinib in the ESAONA study, while Akeso’s AK112 regimen delivered a median overall survival of 27.9 months in squamous NSCLC, slashing death risk by 34% versus a tislelizumab‑chemo combo.
Together, these head‑to‑head victories signal that Chinese innovators are no longer just proving concepts—they’re challenging global first‑line standards and reshaping the future of cancer treatment.
Read more
Chinese Cancer Drugs Shine at ASCO 2026 While Hong Kong Pharma Stocks Slip
The latest ASCO 2026 meeting in Chicago highlighted a wave of breakthroughs in cancer treatment, with Chinese innovators taking center stage. Legend Biotech’s U.S.-listed shares jumped more than 42% after the company announced promising early data on its dual‑target CAR‑T therapy, LB2501, for tough‑to‑treat B‑cell lymphomas. The results will be shown at the European Hematology Association meeting in June.
Across the pond, several foreign drugs made headlines: RevMed’s new RAS inhibitor Daraxonrasib cut the risk of death by 60% and doubled survival for patients with advanced pancreatic cancer; Eli Lilly’s Selpercatinib slashed recurrence or death by 83% in early‑stage lung cancer; and Johnson & Johnson’s Apalutamide offered a fresh option for high‑risk prostate cancer.
Chinese companies set a record, with 12 firms presenting 13 studies in plenary or late‑breaking sessions. Akeso’s bispecific antibody ivonescumab showed it could beat the standard combo of a PD‑1 blocker plus chemotherapy in untreated advanced squamous lung cancer. Bailing Tianheng’s EGFR×HER3 ADC iza‑bren delivered survival gains in both triple‑negative breast cancer and esophageal squamous cell carcinoma.
Other home‑grown advances—including Sunvozertinib, GC101, Envafolimab, IBI363 and Elisrasib—demonstrated the rapid shift from “fast‑follow” to original innovation. Meanwhile, Hong Kong’s innovative‑drug ETFs fell, with the Huixinpu ETF sliding over 3% to a new low.
Read more
Chinese Cancer Breakthroughs Shine at ASCO 2026 – What It Means for Investors
At the 2026 ASCO Annual Meeting, Chinese scientists stole the spotlight, presenting a record‑breaking 95 abstracts. The highlight was Akeso’s ivonescimab, featured in the prestigious Plenary Session for its HARMONi‑6 trial – the first Chinese‑origin oncology drug to earn that honor. The data showed remarkable results in tough cancers like non‑small cell lung cancer and breast cancer, signaling that home‑grown treatments are moving from the lab to the global stage.
For investors, the news dovetails with the performance of the Medical Innovation ETF (Ping An, ticker 516820), which mirrors the CSI Pharmaceutical and Medical Device Innovation Index. This index tracks 30 top‑performing, profit‑driven, and R&D‑focused companies in China’s pharma and medical‑device sectors. As of May 29, 2026, the ten heaviest‑weighted stocks – including WuXi AppTec, Hengrui Medicine, Mindray Medical, and Ping An itself – make up nearly 65 % of the index’s total weight.
The convergence of scientific breakthroughs and strong market representation suggests a bright future for Chinese biotech, offering both patients new treatment options and investors fresh growth opportunities.
Read more